MeSH term
Frequency | Condition_Probility | Anti-Ulcer Agents/therapeutic use | 2 | 16.0 |
English Abstract | 46 | 0.0 |
Humans | 106 | 0.0 |
Animals | 26 | 0.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Infant | 10 | 0.0 |
Research Support, Non-U.S. Gov't | 21 | 0.0 |
Adult | 50 | 0.0 |
*Disease Outbreaks | 10 | 17.0 |
Female | 50 | 0.0 |
Male | 53 | 0.0 |
Uganda/epidemiology | 4 | 16.0 |
Acute Disease | 2 | 0.0 |
Microwaves/*therapeutic use | 7 | 50.0 |
Incidence | 3 | 0.0 |
Population Surveillance | 2 | 1.0 |
Risk Factors | 6 | 0.0 |
Seasons | 2 | 1.0 |
Time Factors | 11 | 0.0 |
Antibodies, Viral/blood | 6 | 5.0 |
Hantaan virus/*immunology | 3 | 75.0 |
Hemorrhagic Fever with Renal Syndrome/*prevention & control | 3 | 100.0 |
Gerbillinae | 2 | 5.0 |
Mice | 11 | 0.0 |
Case-Control Studies | 2 | 0.0 |
China/epidemiology | 6 | 3.0 |
*Disease Reservoirs | 8 | 32.0 |
Hantaan virus/immunology/*isolation & purification | 2 | 100.0 |
Cohort Studies | 11 | 0.0 |
Comparative Study | 11 | 0.0 |
Hydrolysis | 2 | 0.0 |
Immunoglobulin G/blood | 3 | 1.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Milk/*immunology | 2 | 33.0 |
Chronic Disease | 4 | 0.0 |
Middle Aged | 34 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Africa/epidemiology | 2 | 8.0 |
Adolescent | 26 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
*Infant Food | 2 | 5.0 |
Prospective Studies | 8 | 0.0 |
Aged | 12 | 0.0 |
Prognosis | 4 | 0.0 |
Child | 12 | 0.0 |
Otitis Media/*complications | 2 | 100.0 |
Recurrence | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 5 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Disease Outbreaks | 3 | 5.0 |
Acupuncture Points | 3 | 50.0 |
Antibody Formation/drug effects/radiation effects | 2 | 100.0 |
Drug Therapy, Combination | 2 | 0.0 |
Immunity, Cellular/drug effects/radiation effects | 2 | 66.0 |
Amino Acid Sequence | 2 | 0.0 |
Base Sequence | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Age Factors | 4 | 0.0 |
Risk Assessment | 2 | 0.0 |
*Disability Evaluation | 2 | 20.0 |
Retrospective Studies | 5 | 0.0 |
*Severity of Illness Index | 2 | 3.0 |
World Health Organization | 5 | 6.0 |
Infant, Newborn | 4 | 0.0 |
Postoperative Complications | 2 | 1.0 |
Animals, Newborn | 2 | 0.0 |
Antigens, Viral/metabolism | 4 | 18.0 |
Swine | 2 | 0.0 |
Democratic Republic of the Congo/epidemiology | 9 | 90.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Rabbits | 2 | 0.0 |
Health Personnel | 2 | 11.0 |
Hemorrhagic Fever, Ebola/*epidemiology/*immunology/transmission | 2 | 100.0 |
Patient Isolation | 2 | 50.0 |
Contact Tracing | 2 | 33.0 |
Epidemiologic Factors | 3 | 50.0 |
Body Fluids/virology | 2 | 66.0 |
Housing | 2 | 15.0 |
Child, Preschool | 4 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Microwaves/therapeutic use | 2 | 100.0 |
Remission Induction | 3 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Hemodynamic Processes | 2 | 1.0 |
Environment | 3 | 3.0 |
Adsorption | 2 | 1.0 |
Combined Modality Therapy | 4 | 0.0 |
Biopsy | 2 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
RNA, Viral/analysis | 2 | 0.0 |
Epithelium/virology | 2 | 25.0 |
Hemorrhagic Fever with Renal Syndrome/*pathology/*virology | 2 | 100.0 |
Rats | 5 | 0.0 |
*Electromagnetic Fields | 5 | 17.0 |
Evaluation Studies | 2 | 0.0 |
Hypothalamo-Hypophyseal System/*physiopathology | 2 | 3.0 |
Pituitary-Adrenal System/*physiopathology | 2 | 8.0 |
Antigens, Viral/*analysis | 3 | 6.0 |
Hantavirus/*isolation & purification | 2 | 100.0 |
Hemorrhagic Fever with Renal Syndrome/*diagnosis | 2 | 100.0 |
Hemagglutination Inhibition Tests | 3 | 6.0 |
Muridae/*microbiology | 2 | 100.0 |
Rats/*microbiology | 3 | 100.0 |
Serotyping | 6 | 2.0 |
Reproducibility of Results | 2 | 0.0 |
Hemorrhagic Fever with Renal Syndrome/*transmission | 2 | 100.0 |
Mites/*microbiology | 2 | 100.0 |
Hantavirus/*classification | 2 | 66.0 |
Muridae/microbiology | 4 | 100.0 |
Rosette Formation | 2 | 0.0 |
Hantavirus/*immunology | 4 | 80.0 |
Hemorrhagic Fever with Renal Syndrome/*epidemiology | 5 | 100.0 |
*Viral Vaccines | 2 | 12.0 |
Hemorrhagic Fever with Renal Syndrome/*immunology | 2 | 40.0 |
Antibodies, Viral/analysis | 4 | 3.0 |
China | 5 | 1.0 |
Hantavirus/immunology | 3 | 75.0 |
Carrier State/*epidemiology | 2 | 50.0 |
Syndrome | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Radiation Dosage | 2 | 2.0 |